Business Context and Reporting Period
Company: OKYO Pharma Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 23, 2026
Context: The filing discloses a transaction involving the purchase of company shares by a Non-Executive Director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific insider transaction rather than periodic financial performance.
Material Changes
Insider Transaction: On July 23, 2026, Non-Executive Director John Brancaccio purchased 5,000 ordinary shares of the Company on NASDAQ.
Transaction Price: $1.48 per share.
Post-Transaction Holdings: The purchase brings Mr. Brancaccio's total holding to 35,201 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the director's share purchase and incorporates the news announcement as Exhibit 99.1.
Investor Verification Checklist
- Verify the total number of shares held by John Brancaccio (35,201) against the company's latest beneficial ownership reports.
- Confirm the market price of OKYO Pharma shares on NASDAQ on July 23, 2026, to validate the $1.48 transaction price.
- Review the attached Exhibit 99.1 for any additional context regarding the director's intent or future plans not detailed in the summary.